[go: up one dir, main page]

WO2008093737A1 - アミド誘導体 - Google Patents

アミド誘導体 Download PDF

Info

Publication number
WO2008093737A1
WO2008093737A1 PCT/JP2008/051418 JP2008051418W WO2008093737A1 WO 2008093737 A1 WO2008093737 A1 WO 2008093737A1 JP 2008051418 W JP2008051418 W JP 2008051418W WO 2008093737 A1 WO2008093737 A1 WO 2008093737A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
hydrogen atom
alkyl group
group
amide derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/051418
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Nakahira
Yohei Ikuma
Nobuhisa Fukuda
Tomonori Kobayashi
Shinya Tosaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Priority to EP08704181A priority Critical patent/EP2119702A4/en
Priority to JP2008556153A priority patent/JPWO2008093737A1/ja
Priority to US12/524,921 priority patent/US20100056497A1/en
Publication of WO2008093737A1 publication Critical patent/WO2008093737A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明は、レニン阻害剤として有用な式（Ｉ）の化合物、またはその薬学上許容される塩を提供する。 ［式中、Ｒ１ａは、水素原子、置換されてもよいＣ１－６アルキル基等であり；Ｒ１ｂは、置換されたＣ１－６アルコキシ基等であり；Ｒ１ｃは、水素原子、置換されてもよいＣ１－６アルコキシ基等であり；Ｒ２は、水素原子、置換されてもよいＣ１－６アルキル基等であり；Ｒ３ａ、Ｒ３ｂ、Ｒ３ｃおよびＲ３ｄは、各々独立して、同一または異なって、基：－Ａ－Ｂ（ここにおいて、Ａは、単結合、－（ＣＨ２）ｓＯ－、－（ＣＨ２）ｓＮ（Ｒ４）ＣＯ－等であり、Ｂは、水素原子、置換されてもよいＣ１－６アルキル基等）等であり；Ｒ４は、水素原子、置換されてもよいＣ１－６アルキル基等であり；ｓは、０等であり；ｎは、１等である。］
PCT/JP2008/051418 2007-01-31 2008-01-30 アミド誘導体 Ceased WO2008093737A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08704181A EP2119702A4 (en) 2007-01-31 2008-01-30 amide derivative
JP2008556153A JPWO2008093737A1 (ja) 2007-01-31 2008-01-30 アミド誘導体
US12/524,921 US20100056497A1 (en) 2007-01-31 2008-01-30 Amide derivative

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2007022513 2007-01-31
JP2007-022513 2007-01-31
JP2007-050871 2007-02-28
JP2007050871 2007-02-28
JP2007-338384 2007-12-27
JP2007338384 2007-12-27

Publications (1)

Publication Number Publication Date
WO2008093737A1 true WO2008093737A1 (ja) 2008-08-07

Family

ID=39674045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051418 Ceased WO2008093737A1 (ja) 2007-01-31 2008-01-30 アミド誘導体

Country Status (5)

Country Link
US (1) US20100056497A1 (ja)
EP (1) EP2119702A4 (ja)
JP (1) JPWO2008093737A1 (ja)
TW (1) TW200901999A (ja)
WO (1) WO2008093737A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072649A1 (ja) * 2007-12-08 2009-06-11 Dainippon Sumitomo Pharma Co., Ltd. ４－アリールフェニル誘導体
WO2009078481A1 (ja) * 2007-12-19 2009-06-25 Dainippon Sumitomo Pharma Co., Ltd. 二環性へテロ環誘導体
US20100197715A1 (en) * 2009-01-27 2010-08-05 Sabine Kolczewski Piperidine derivatives
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体
JP2011157391A (ja) * 2008-06-19 2011-08-18 Takeda Chem Ind Ltd 複素環化合物およびその用途
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8470816B2 (en) 2007-12-03 2013-06-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969831B (zh) * 2023-08-01 2025-09-23 菏泽皓元医药科技有限公司 一种莫奈太尔的中间体及其制备方法

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021672A1 (en) 1991-05-30 1992-12-10 G. D. Searle & Co. Pla2 inhibitors
JPH0812605A (ja) 1994-04-28 1996-01-16 Chisso Corp 液晶性化合物、液晶組成物および液晶表示素子
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5817678A (en) 1995-11-22 1998-10-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
WO2002002525A2 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2002010172A1 (fr) 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2004007491A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
WO2004028467A2 (en) 2002-09-25 2004-04-08 University Of Wyoming Diagnosis of bovine viral diarrhea virus
WO2004096773A1 (en) 2003-04-25 2004-11-11 Eli Lilly And Company Quinolone derivatives
WO2004110955A1 (de) * 2003-06-12 2004-12-23 Robert Bosch Gmbh Verfahren zur herstellung eines isolierenden keramik-verbund-werkstoffes und isolierender keramik-verbund-werkstoff
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2005053663A2 (en) * 2003-11-24 2005-06-16 Eli Lilly And Company Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
WO2005082872A1 (ja) 2004-03-02 2005-09-09 Dainippon Sumitomo Pharma Co., Ltd. ベンゾチアジン－３－オン化合物及びその製造中間体
WO2005085275A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
WO2005095357A2 (en) 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2006039325A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006066896A2 (en) 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
WO2006069788A1 (en) 2004-12-30 2006-07-06 Novartis Ag Organic compounds
WO2006094763A1 (en) 2005-03-09 2006-09-14 Novartis Ag 3,4,5-substituted piperidine compounds
WO2006100036A1 (en) 2005-03-23 2006-09-28 Novartis Ag 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849620B2 (en) * 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005510523A (ja) * 2001-11-09 2005-04-21 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
AU2004247487B2 (en) * 2003-06-17 2010-05-20 Pfizer Inc. N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
RU2010129690A (ru) * 2007-12-19 2012-01-27 Дайниппон Сумитомо Фарма Ко., Лтд. (Jp) Бициклические гетероциклические производные

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021672A1 (en) 1991-05-30 1992-12-10 G. D. Searle & Co. Pla2 inhibitors
JPH0812605A (ja) 1994-04-28 1996-01-16 Chisso Corp 液晶性化合物、液晶組成物および液晶表示素子
WO1997018813A1 (en) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5817678A (en) 1995-11-22 1998-10-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1999054321A1 (en) 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors
WO2002002525A2 (en) 2000-06-30 2002-01-10 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2002010172A1 (fr) 2000-08-01 2002-02-07 Aventis Pharma Sa Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
WO2004007491A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
WO2004028467A2 (en) 2002-09-25 2004-04-08 University Of Wyoming Diagnosis of bovine viral diarrhea virus
WO2004096773A1 (en) 2003-04-25 2004-11-11 Eli Lilly And Company Quinolone derivatives
WO2004110955A1 (de) * 2003-06-12 2004-12-23 Robert Bosch Gmbh Verfahren zur herstellung eines isolierenden keramik-verbund-werkstoffes und isolierender keramik-verbund-werkstoff
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
WO2005053663A2 (en) * 2003-11-24 2005-06-16 Eli Lilly And Company Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
WO2005085275A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis c virus ns3 protease
WO2005082872A1 (ja) 2004-03-02 2005-09-09 Dainippon Sumitomo Pharma Co., Ltd. ベンゾチアジン－３－オン化合物及びその製造中間体
WO2005095357A2 (en) 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2006039325A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006066896A2 (en) 2004-12-23 2006-06-29 Novartis Ag Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
WO2006069788A1 (en) 2004-12-30 2006-07-06 Novartis Ag Organic compounds
WO2006094763A1 (en) 2005-03-09 2006-09-14 Novartis Ag 3,4,5-substituted piperidine compounds
WO2006100036A1 (en) 2005-03-23 2006-09-28 Novartis Ag 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension

Non-Patent Citations (43)

* Cited by examiner, † Cited by third party
Title
"Jikken-Kagaku-Koza", vol. 22, MARUZEN
"Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC
"Protective Groups in Organic Synthesis", JOHN WILEY & SONS, INC.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 1621, 2006, pages 16
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 13, 2005, pages 59
CHEM. PHARM. BULL., vol. 40, 1992, pages 102
CHEM. PHARM. BULL., vol. 46, 1998, pages 1716
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 46, 1998, pages 1716
CIRCULATION, vol. 111, no. 8, 2005, pages 10 12 - 8
CURR DIAB REP., vol. 6, no. 1, 2006, pages 8 - 16
CURR HYPERTENS REP., vol. 6, no. 2, 2004, pages 129 - 32
HYPERTENSION, vol. 42, no. 6, 2003, pages 137 - 43
J AM SOC NEPHROL, vol. 16, 2005, pages 592 - 599
J EXP MED., vol. 106, no. 3, 1957, pages 439 - 53
J HYPERTENS, vol. 23, no. 1, 2005, pages 9 - 17
J HYPERTENS, vol. 24, no. 4, 2006, pages 82
J. AM. CHEM. SOC., vol. 123, 2001, pages 6989
J. CHEM. SOC. PERKIN TRANS, vol. 2, 1988, pages 691
J. COMBINATORIAL CHEMISTRY, vol. 8, 2006, pages 469
J. MED. CHEM., vol. 26, 1983, pages 507
J. OR G. CHEM., vol. 57, 1992, pages 7194
J. OR G. CHEM., vol. 61, 1996, pages 6033
J. OR G. CHEM., vol. 70, 2005, pages 4360
J. OR G. CHEM., vol. 70, 2005, pages 6956
J. OR G. CHEM., vol. 71, 2006, pages 6522
J. ORG. CHEM., vol. 61, 1996, pages 3849
J. ORG. CHEM., vol. 63, 1998, pages 370
J. ORG. CHEM., vol. 68, 2003, pages 4120
J. ORG. CHEM., vol. 70, 2005, pages 2195
NAT REV DRUG DISCOV., vol. 1, no. 8, 2002, pages 621 - 36
PHYSIOL. REV., vol. 86, 2006, pages 747 - 803
R. C. LAROQUE: "Comprehensive Organic transformation", 1989, VCH PUBLISHER INC
R. C. LAROQUE: "Comprehensive Organic transformation", 1989, VCH PUBLISHER INC.
R. C. LAROQUE: "Comprehensive Organic transformation", vol. 61, 1989, VCH PUBLISHER INC., pages: 3849
See also references of EP2119702A4 *
SYNTH. COMMUN., vol. 27, 1997, pages 2943
SYNTH. COMMUN., vol. 29, 1999, pages 591
SYNTHETIC COMMUNICATIONS, vol. 34, 2004, pages 219
TETRAHEDRON LETTERS, vol. 43, 2002, pages 4275
TETRAHEDRON LETTERS, vol. 46, 2005, pages 7495
TETRAHEDRON: ASYMMETRY, vol. 16, 2005, pages 2599
TETRAHEDRON: ASYMMETRY, vol. 17, 2006, pages 993
TETRAHEDRON: ASYMMETRY, vol. 8, 1997, pages 3685

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
US8470816B2 (en) 2007-12-03 2013-06-25 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
WO2009072649A1 (ja) * 2007-12-08 2009-06-11 Dainippon Sumitomo Pharma Co., Ltd. ４－アリールフェニル誘導体
WO2009078481A1 (ja) * 2007-12-19 2009-06-25 Dainippon Sumitomo Pharma Co., Ltd. 二環性へテロ環誘導体
JP5484069B2 (ja) * 2007-12-19 2014-05-07 大日本住友製薬株式会社 二環性へテロ環誘導体
US20110190278A1 (en) * 2007-12-19 2011-08-04 Dainippon Sumitomo Pharma Co. Bicyclic heterocyclic derivative
US8389511B2 (en) 2007-12-19 2013-03-05 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic derivative
US9221836B2 (en) 2008-06-19 2015-12-29 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP2011157391A (ja) * 2008-06-19 2011-08-18 Takeda Chem Ind Ltd 複素環化合物およびその用途
US8466282B2 (en) 2008-06-19 2013-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9045436B2 (en) 2008-06-19 2015-06-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8664380B2 (en) 2008-06-19 2014-03-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US9067911B2 (en) 2009-01-27 2015-06-30 Hoffmann-La Roche Inc. Piperidine derivatives
US20100197715A1 (en) * 2009-01-27 2010-08-05 Sabine Kolczewski Piperidine derivatives
EP2447264A4 (en) * 2009-06-24 2012-12-12 Dainippon Sumitomo Pharma Co N-SUBSTITUTED CYCLIC AMINO DERIVATIVE
US8658639B2 (en) 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
JPWO2010150840A1 (ja) * 2009-06-24 2012-12-10 大日本住友製薬株式会社 Ｎ−置換−環状アミノ誘導体
WO2010150840A1 (ja) 2009-06-24 2010-12-29 大日本住友製薬株式会社 Ｎ－置換－環状アミノ誘導体

Also Published As

Publication number Publication date
JPWO2008093737A1 (ja) 2010-05-20
TW200901999A (en) 2009-01-16
EP2119702A4 (en) 2010-12-08
US20100056497A1 (en) 2010-03-04
EP2119702A1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
WO2008136457A1 (ja) 含窒素芳香族誘導体
WO2008093737A1 (ja) アミド誘導体
WO2009078481A1 (ja) 二環性へテロ環誘導体
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
WO2009020140A1 (ja) アダマンチルウレア誘導体
WO2009072621A1 (ja) 置換ジヒドロアゾール化合物及び有害生物防除剤
EP1679309A4 (en) ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
WO2008111473A1 (ja) グルコキナーゼ活性化物質
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
WO2008126933A3 (en) Process for producing pesticidal benzamide compounds
WO2008120754A1 (ja) ピコリン酸アミド化合物
WO2008126831A1 (ja) ピロール誘導体のアトロプ異性体
WO2010066629A3 (en) Novel azaindoles
WO2007099548A3 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
WO2007103508A3 (en) Ligands for nematode nuclear receptors and uses thereof
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
WO2009014217A1 (ja) 二環性ピロール誘導体
WO2009063991A1 (ja) ピリドオキサゼピン誘導体およびその用途
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2009019815A1 (ja) 新規γセクレターゼ阻害剤
WO2007119004A3 (fr) Methode de diagnostic in vitro ou ex vivo de desordres psychiatriques et/ou de dysbioses intestinales
ZA200802166B (en) Use of bipyridine compound caerulomycin a'derivatives and analogs thereof as immunosuppresive agents
WO2007032019A3 (en) Process for preparing valsartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704181

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2008556153

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12524921

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008704181

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)